Suggested remit: To appraise the clinical and cost effectiveness of linzagolix within its marketing authorisation for treating uterine fibroids.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6190

Project Team

Project lead Leena Issa

Email enquiries


Companies sponsors Theramex (linzagolix)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups None
Professional groups Royal College of Physicians
Associated public health groups None
Comparator companies AstraZeneca (goserelin) (confidentiality agreement signed, participating)
  Ferring Pharmaceuticals (triptorelin) (confidentiality agreement not signed, not partipating)
  Gedeon Richter (relugolix-estradiol-norethisterone acetate) (confidentiality agreement signed, participating)
  Ipsen (triptorelin) (confidentiality agreement not signed, not partipating)
  Takeda UK (leuprorelin) (confidentiality agreement not signed, not partipating)
  Typharm (leuprorelin) (confidentiality agreement not signed, not partipating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups None


Key events during the development of the guidance:

Date Update
04 June 2024 Committee meeting
04 June 2024 Declaration of interests
05 February 2024 - 26 February 2024 Draft guidance
09 January 2024 Committee meeting
22 November 2023 Please note the update to the committee meeting date. The committee meeting is now scheduled to take place on Tuesday 9 January 2024.
04 July 2023 Invitation to participate
21 March 2023 - 20 April 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
21 March 2023 In progress. Scoping commenced
09 September 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual